Safety of intravenous use of anakinra in pediatric inflammatory conditions: a retrospective multicenter study
Authors' conclusion
Intravenous administration of anakinra appears to be safe and not associated with severe adverse events.
Study context
- Population
- Pediatric patients who received intravenous anakinra, January 1st, 2017, to February 29th 2024: underlying rheumatologic diseases, onco-hematologic diseases or severe systemic infections59 (52.2%) admitted to ICU
- Participants
- 113 patients
- Outcome
- Safety of IV anakinra (anakinra-related adverse events)
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
Adverse events
Adverse events in 10 of 113 treated children
8.8%
Observational data: associations, not effects.
Further findings
Deaths
- 16 patients died
- 14.2%
- Of those who died, 10 on ongoing anakinra, median treatment duration 27 days (range 2-42)
- Of those who died, 6 had discontinued the drug several days earlier
Safety
Transient elevation of liver or pancreatic enzymes
- 7 patients
- 6.2%
- Most common events
Maculopapular rash
- 2 patients
- 1.2%
Anaphylactoid reaction immediately after infusion
- 1 patient
- 0.9%
Original publication
Safety of intravenous use of anakinra in pediatric inflammatory conditions: a retrospective multicenter study. Pediatr Rheumatol Online J. Published 5 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →